Reliability Becomes the Advantage: Quality Maturity and the Drug Shortage Test
Drug shortages continue to expose a hard truth for pharmaceutical leaders: supply reliability is no longer only an operational metric. It is a patient-access issue, a customer-trust issue, a regulatory issue, and increasingly a source of competitive differentiation. When medicines are unavailable, providers, patients, payers, and policymakers do not see an internal manufacturing issue. They see a failure of reliability.
ASHP reported 223 active drug shortages in 2026, trending upward for the second consecutive quarter, with controlled substances accounting for 15% of active shortages. FDA notes that shortages can result from manufacturing and quality problems, delays, discontinuations, or other supply disruptions, and the agency works with manufacturers to prevent or reduce shortage impacts.
The FDA’s Center for Drug Evaluation and Research is also advancing its Quality Management Maturity program, which aims to encourage drug manufacturers to implement quality management practices that go beyond current good manufacturing practice requirements. For CEOs, this signals a shift: baseline compliance is no longer enough to demonstrate reliability.
In pharma, quality maturity is becoming a commercial advantage, not only a compliance requirement.
Drug Shortages Are a Reliability Signal
Drug shortages are often discussed as market events, but they are usually rooted in operating realities: aging assets, constrained capacity, low-margin products, quality investigations, supplier issues, batch failures, maintenance delays, workforce gaps, or poor visibility into production risk. Each shortage creates downstream cost and friction across hospitals, pharmacies, wholesalers, payers, and patients.
For manufacturers, shortages can damage customer trust and regulatory confidence. They can also expose weaknesses in quality systems, escalation routines, deviation management, supplier qualification, and production planning. In a market where providers and distributors increasingly value dependable supply, reliability becomes a strategic asset.
The question for pharma leaders is not only how to respond once a shortage occurs. It is how to build a system that sees reliability risk earlier and acts before quality or supply issues become market-facing events.
Quality Maturity Must Move Beyond Compliance
Current good manufacturing practice is the minimum standard, but mature quality systems go further. They create disciplined routines for monitoring process health, learning from deviations, strengthening preventive actions, improving knowledge management, and using leading indicators to anticipate risk.
FDA’s QMM work reflects this broader shift. The agency’s 2026 Federal Register notice indicated that CDER intends to continue its voluntary QMM Prototype Assessment Protocol Evaluation Program to evaluate drug manufacturing establishments’ quality management practices and provide actionable feedback. This is important because mature quality management is tied to supply-chain robustness and shortage prevention.
For CEOs, quality maturity cannot be delegated only to quality assurance. It depends on manufacturing leadership, maintenance reliability, engineering, procurement, training, planning, technical operations, and site management cadence. Quality outcomes are created by the daily operating system of the plant.
Quality Data Must Become Management Action
Pharmaceutical manufacturers often have large volumes of quality data, but data volume does not guarantee operating control. Deviation trends, environmental monitoring, maintenance history, supplier performance, batch record errors, cycle times, and complaint signals can all point to reliability risk. The issue is whether leaders can translate those signals into action quickly enough.
A mature quality system turns data into management routines. Site leaders review the right leading indicators, supervisors understand where standards are drifting, technical teams address recurring causes rather than symptoms, and enterprise leaders can see which products or sites are creating the greatest risk. Without that cadence, quality information remains fragmented and reactive.
This is especially important for multi-site networks and companies using contract manufacturers. Enterprise leaders need a consistent way to compare risk, escalate issues, and allocate support across the network. Quality maturity depends on making performance visible at the level where decisions can be made.
Reliability Is Also a Customer and Portfolio Issue
Supply reliability increasingly affects customer relationships. Wholesalers, health systems, pharmacies, and government purchasers value manufacturers that can deliver consistently, especially in categories where alternatives are limited or switching creates clinical disruption. A reliable supplier can earn trust even in markets where price pressure is intense.
Reliability also affects portfolio decisions. Products with persistent quality or supply problems consume management attention, regulatory resources, and working capital. Pharma leaders need to understand which products can be stabilized, which require investment, and which may not justify the operational burden. Quality maturity therefore supports both day-to-day performance and long-term portfolio discipline.
Reliability Requires Control of the Whole Manufacturing System
Supply reliability is not created by inspection alone. It is created through process capability, equipment uptime, raw-material availability, trained operators, clear standards, deviation discipline, batch-review speed, and leadership routines that surface issues early. The strongest manufacturers manage quality, throughput, and reliability together rather than treating them as competing priorities.
This is especially important for products with fragile economics or complex manufacturing requirements. When margins are thin, it is tempting to underinvest in reliability, but the long-term cost can be greater: shortages, remediation, warning letters, customer loss, and production disruption. Mature quality systems reduce risk by making problems visible before they compound.
The industry is moving toward a world where supply reliability and quality maturity can influence customer selection, regulatory confidence, and market resilience. Companies that can demonstrate dependable operations may earn advantages that go beyond compliance.
The Brooks International Perspective
From Brooks International’s perspective, quality maturity is an operating discipline that must be embedded in the management system of the enterprise. The objective is not to add more documentation for its own sake. The objective is to make quality, reliability, and supply performance controllable.
Brooks International would focus on the practical routines that determine whether quality maturity is real: daily production control, deviation review cadence, maintenance planning, supplier issue escalation, training effectiveness, batch-release visibility, corrective-action follow-through, and leadership accountability at the site and network levels.
The strongest opportunities often come from connecting quality metrics to operational decision-making. If a deviation trend signals process instability, leadership must understand the capacity, maintenance, training, and supply implications. If a supplier issue threatens release timing, procurement, quality, and production must act through a shared escalation process. If batch review becomes a bottleneck, the organization must manage it as a supply constraint.
For CEOs, the implication is that quality maturity should be reviewed with the same seriousness as commercial growth, capital allocation, and pipeline performance. A recurring deviation, a delayed release, or a supplier weakness can become a revenue, access, and reputation issue. Leaders need a cadence that treats these signals as enterprise risk rather than site-level noise. The same cadence should also connect quality risk to commercial and supply priorities, ensuring that leaders understand which shortages, customer commitments, or product launches could be affected if a quality issue is not resolved quickly and permanently. In a networked manufacturing model, the strongest quality systems make the business impact of quality visible without weakening scientific rigor or compliance discipline across sites.
Brooks International’s perspective is that quality maturity becomes enterprise value when it reduces risk, improves release reliability, protects patient access, and gives leaders confidence that performance is being controlled rather than explained after the fact.
What Pharmaceutical Leaders Should Be Asking Now
The leadership agenda should focus on whether quality and supply reliability are being managed through leading indicators and daily operating control:
- Which products, sites, processes, or suppliers create the greatest shortage exposure?
- Are quality risks visible early enough for leaders to intervene before they affect supply?
- Do manufacturing, quality, maintenance, and planning teams operate from the same reliability priorities?
- Are deviations and corrective actions resolved with speed, rigor, and ownership?
- Can the organization quantify the business impact of batch failures, release delays, remediation, and supply interruptions?
- Does the management system reinforce quality maturity every day, or does it rely on periodic audits and reactive escalation?
These questions matter because reliability is built before a shortage appears. Once patients and providers are affected, the cost of operating weakness is already visible.
The Leadership Imperative
Drug shortages have made supply reliability a CEO-level issue. Regulators, customers, and patients increasingly expect manufacturers to prove that quality systems are mature, proactive, and capable of sustaining uninterrupted supply.
For pharmaceutical leaders, the mandate is to move beyond compliance as a defensive posture and build quality maturity as a source of operational advantage. That requires strong plant discipline, clear accountability, better leading indicators, and leadership routines that make risk actionable.
In the next phase of pharmaceutical manufacturing, the most reliable suppliers will not simply avoid problems. They will win trust because their operating systems are built to prevent them.
